We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
AstraZeneca’s Enhertu slashed the risk of patients’ condition worsening or causing death by 72 percent compared with another drug.
David Fredrickson, the firm’s head of oncology, reportedly said there were tears and cries of surprise when scientists saw the data.
He added: “It’s remarkable to hear the oncology community, as they take the data in, say, ‘Is it possible that we could be offering a cure for some women with advanced disease?'” Susan Galbraith, executive vice president of oncology research, said the results may present “a paradigm shift in the treatment of HER2- positive metastatic breast cancer”.
Enhertu was approved for use on the NHS in England in April for patients who have had two or more other treatments for this cancer type.
The data suggests it may also be effective when used after only one.
Meanwhile, drug combination VS-6766 and defactinib looks promising against treatment-resistant ovarian cancer.
In a study of 24 patients, tumours shrank for 46 percent of those who took both, compared to less than 13 percent for chemotherapy and 14 percent to hormone therapy.
Source: Read Full Article